Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence IQRTPKIQVYSRHPAENGKSNFLNcYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYAcRVNHVTLSQPKIVKWDRDM
Primary information
sequence IDSeq_3876
Peptide sequenceIQRTPKIQVYSRHPAENGKSNFLNcYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYAcRVNHVTLSQPKIVKWDRDM
CancerPDF_ID CancerPDF_ID3520, CancerPDF_ID3846,
PMID27026199,27026199
Protein NameBeta-2-microglobulin,Beta-2-microglobulin
UniprotKB Entry NameB2M_HUMAN,B2MG_HUMAN
FluidUrine,Urine
M/ZNA,NA
ChargeNA,NA
Mass (in Da)NA,NA
fdr11721.51,11721.5
Profiling Technique"CE-MS, Micro-TOF-MS","CE-MS, Micro-TOF-MS"
Peptide Identification techniqueMS-MS,MS-MS
Quantification TechniqueNA,NA
Labelled/Label FreeLabel Free,Label Free
FDRNA,NA
CancerPDF_ID CancerPDF_ID3520, CancerPDF_ID3846,
p-Valueless than 0.05,less than 0.05
SoftwareProteome Discoverer 1.2,Proteome Discoverer 1.2
Length99,99
Cancer TypeBladder cancer,Bladder cancer
DatabaseUniprot Human non-redundant Database,Uniprot Human non-redundant Database
ModificationNA,NA
Number of Patients451 for training (341 patients and 110 normal) and 270 for testing(168 primary UBC patients and 102 normal controls);, 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls)
RegulationDifferentially expressed between primary UBC and normal individual,Differentially expressed between recurrence of UBC vs recurrence control
ValidationIndependent Validation,Independent Validation
SensitivityFor testing dataset 91%,For testing dataset 88%
SpecificityFor testing dataset 68%,For testing dataset 51%
AccuracyFor testing dataset 76%,NA
Peptide AtlasNA
IEDB
Primary information
sequence IDSeq_3877
Peptide sequenceIQRTPKIQVYSRHPAENGKSNFLNcYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYAcRVNHVTLSQPKIVKWDRDm
CancerPDF_ID CancerPDF_ID3521, CancerPDF_ID3847,
PMID27026199,27026199
Protein NameBeta-2-microglobulin,Beta-2-microglobulin
UniprotKB Entry NameB2M_HUMAN,B2MG_HUMAN
FluidUrine,Urine
M/ZNA,NA
ChargeNA,NA
Mass (in Da)NA,NA
fdr11737.74,11737.7
Profiling Technique"CE-MS, Micro-TOF-MS","CE-MS, Micro-TOF-MS"
Peptide Identification techniqueMS-MS,MS-MS
Quantification TechniqueNA,NA
Labelled/Label FreeLabel Free,Label Free
FDRNA,NA
CancerPDF_ID CancerPDF_ID3521, CancerPDF_ID3847,
p-Valueless than 0.05,less than 0.05
SoftwareProteome Discoverer 1.2,Proteome Discoverer 1.2
Length99,99
Cancer TypeBladder cancer,Bladder cancer
DatabaseUniprot Human non-redundant Database,Uniprot Human non-redundant Database
Modificationm: Oxidized-Methionine,m:Oxidized Methionine
Number of Patients451 for training (341 patients and 110 normal) and 270 for testing(168 primary UBC patients and 102 normal controls);, 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls)
RegulationDifferentially expressed between primary UBC and normal individual,Differentially expressed between recurrence of UBC vs recurrence control
ValidationIndependent Validation,Independent Validation
SensitivityFor testing dataset 91%,For testing dataset 88%
SpecificityFor testing dataset 68%,For testing dataset 51%
AccuracyFor testing dataset 76%,NA
Peptide AtlasNA
IEDB